Immuno-oncology targets

TARGET DISEASE INDICATIONS STATUS – KEY DATA MILESTONE
ZM008

Lead Molecule
New target. Functions through NK cell based therapy

Prostate Cancer,
B cell lymphoma, glioma, rheumatoid arthritis
  • Strong in vivo efficacy
  • Ongoing clinical risk mitigation studies
  • Development management team in place
IND filing in
Q 4 2020
ZM012

mAb target. Functions through tumour associated antigen/NK cell receptor

Lymphoma and other Undisclosed indications Unique Clone identification in process Animal Efficacy –
Q 3 2020
ZM014

mAb target. Functions through tumour NK cell receptor

Lymphoma Unique Clone identification in process Animal Efficacy –
Q 4 2020

2

Molecules for NK cell and cell targets under development

Future targets of interest

Other Innate Immunity Targets

Novel Targets

Academic collaboration in the US